- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06918561
Evaluering av effekten av neothelium FT i behandlingen av kroniske åpne sår
Evaluering av effektiviteten av neothelium FT i helbredelse av kroniske åpne sår: en randomisert kontrollert multisenterstudie
This is a randomized controlled crossover trial evaluating the efficacy of NeoThelium FT in conjunction with standard of care vs. standard of care alone in treating chronic open wounds.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
This research will take place across multiple medical centers, where both researchers and participants will know which treatment is being used (open label). Patients who agree to participate and meet the study requirements during screening will be randomly assigned to one of two groups: either standard of care (SOC) alone, or SOC plus NeoThelium FT.
The study includes a crossover component for subjects in the SOC arm. At treatment visit 13 (approximately 84 days post-randomization), SOC arm subjects not having achieved complete wound closure, and still meeting the inclusion/exclusion criteria, are eligible to cross over to the IP arm (SOC plus NeoThelium FT). Crossover subjects will begin IP arm treatment with weekly NeoThelium FT applications for up to 12 treatment visits. The subject will continue follow-up per the original schedule. As this is a post-marketing study, it will gather information regarding the efficacy of treatment while also supporting insurance reimbursement decisions. All subjects will complete two-week screening phase prior to being randomized into a treatment arm. Treatment arms will consist of NeoThelium FT in conjunction with standard of care, vs. standard of care alone. The primary endpoint will be the percentage of target ulcers that achieve complete wound closure within 12 weeks. Secondary endpoints consist of wound percentage area reduction rates and pain assessment.
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Angelina Ferguson, DNP
- Telefonnummer: (985) 629-4013
- E-post: info@sygnola.com
Studer Kontakt Backup
- Navn: Sarah Moore, MBE
- Telefonnummer: (985) 629-4013
- E-post: info@sygnola.com
Studiesteder
-
-
Louisiana
-
Denham Springs, Louisiana, Forente stater, 70726
- Rekruttering
- MedCentris of Denham Springs
-
Hovedetterforsker:
- Monique Consoer, NP
-
Ta kontakt med:
- Tabatha Yent
- E-post: tabatha.yent@medcentris.com
-
Hammond, Louisiana, Forente stater, 70403
- Rekruttering
- MedCentris of Hammond
-
Hovedetterforsker:
- Chris Keaton, NP
-
Ta kontakt med:
- Chelsea Smith, RN
- E-post: Chelsea.smith@medcentris.com
-
Ta kontakt med:
- Melanie Knox, LPN
- E-post: Melanie.knox@medcentris.com
-
Lafayette, Louisiana, Forente stater, 70507
- Fullført
- MedCentris of Carencro
-
Leesville, Louisiana, Forente stater, 71146
- Rekruttering
- MedCentris of Leesville
-
Hovedetterforsker:
- Stefanie Corley, FNP
-
Ta kontakt med:
- Brandi Shuff
- E-post: Brandi.shuff@medcentris.com
-
Many, Louisiana, Forente stater, 71449
- Rekruttering
- MedCentris of Many
-
Hovedetterforsker:
- Stefanie Corley, FNP
-
Ta kontakt med:
- Brandi Shuff
- E-post: Brandi.Shuff@medcentris.com
-
Marksville, Louisiana, Forente stater, 71351
- Rekruttering
- MedCentris of Marksville
-
Hovedetterforsker:
- Averie Rachal, FNP
-
Ta kontakt med:
- Laura Whittington
- E-post: Laura.whittington@medcentris.com
-
Metairie, Louisiana, Forente stater, 70001
- Rekruttering
- MedCentris of Metairie
-
Ta kontakt med:
- Ninya Powell
- E-post: ninya.powell@medcentris.com
-
Hovedetterforsker:
- Sarah Logrande, NP
-
Minden, Louisiana, Forente stater, 71055
- Rekruttering
- MedCentris of Minden
-
Hovedetterforsker:
- Taheera Forbes, NP
-
Ta kontakt med:
- Brianna Thompas
- E-post: brianna.thompson@medcentris.com
-
Monroe, Louisiana, Forente stater, 71201
- Har ikke rekruttert ennå
- MedCentris of Monroe
-
Hovedetterforsker:
- Libbi Trawick, NP
-
Ta kontakt med:
- Tiffany Dew
- E-post: Tiffany.dew@medcentris.com
-
Slidell, Louisiana, Forente stater, 70458
- Rekruttering
- MedCentris of Slidell
-
Hovedetterforsker:
- Katie Schloegel, FNP
-
Ta kontakt med:
- Donyille Singletary, RN
- Telefonnummer: 985-602-1215
- E-post: Donyille.singletary@medcentris.com
-
-
Mississippi
-
D'Iberville, Mississippi, Forente stater, 39540
- Fullført
- MedCentris of D'iberville
-
McComb, Mississippi, Forente stater, 39648
- Fullført
- MedCentris of McComb
-
Natchez, Mississippi, Forente stater, 39120
- Fullført
- MedCentris of Natchez
-
Southaven, Mississippi, Forente stater, 38671
- Rekruttering
- MedCentris of Southaven
-
Hovedetterforsker:
- Carlene McAllister, NP
-
Ta kontakt med:
- De'Nyia Woods
- E-post: denyia.woods@medcentris.com
-
-
New York
-
Brooklyn, New York, Forente stater, 11234
- Rekruttering
- Northeast Podiatry Consultant
-
Ta kontakt med:
- Thomas Hayes
- E-post: thomas@simonfootandankle.com
-
Hovedetterforsker:
- David Simon, DPM, FACFAS
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Male or Female, 18 years of age or older
- Subject has a medical diagnosis of "other" Open wound
- Subject has a chronic open wound present for 4 weeks or greater (documented in medical record), and less than 12 months duration if being treated with continuous SOC
- Subject has a chronic open wound with a historical wound measurement showing less than 25% healing within 14 days prior to screening
- Subject has a chronic open wound with screening wound measurement showing less than 25% healing within 14 days prior to randomization
- Subject has an Open wound without infection or clinically visible exposed bone
- Index wound is a minimum of 0.5cm2 and a maximum of 25cm2 at first treatment visit
- Index ulcer has a maximum depth of 1cm at screening visit 1
- The chronic open wound is treated with offloading therapy, if applicable to location, while standing, sitting, and lying down for 14 days prior to randomization
- Adequate circulation of wounds located below the knee demonstrated by an ABI of >0.7 and <1.3, or TBI of >0.6 within 30 days prior to randomization OR an arterial ultrasound noted with patent circulation and without significant stenosis 90 days prior to randomization.
- Index ulcer is free of infection prior to randomization and during screening phase.
- Index ulcer is free of necrotic debris prior to NeoThelium FT application
- Female subjects of childbearing potential having a negative pregnancy test prior to randomization
- Index ulcer is free of infection prior to randomization and during screening phase noted with the NERDS Assessment. Infection must be adequately treated and controlled prior to randomization.
- Subject is able and willing to follow the protocol requirements
- Subject had signed informed consent
- If 2 or more ulcers are present, the ulcers must be separated by at least 2 cm
Exclusion Criteria:
- Subject with a wound diagnosis of diabetic foot wound, pressure wound, venous leg wound, burn wound, or alternative diagnosis other than "open wound"
- Subject has a known life expectancy of <1 year
- Subject is unable to comply with protocol treatment
- Subject has major uncontrolled medical disorders in the opinion of the investigator, such as serious cardiovascular, renal, liver, pulmonary, autoimmune, palliative care, or inherited blood disorders that may affect wound healing.
- Subject actively being treated for malignant disease or history of malignancy or radiation therapy at the site of wound
- Subject has comorbid conditions that may compromise subject safety in the opinion of the investigator
- Known contraindications to tissue-engineered allograft
- Concurrent participation in alternative clinical trial that involves investigational drug or product interfering with wound treatment and/or healing
- Subject is pregnant or breastfeeding
- Subject with history of immunosuppressant treatment (systemic corticosteroids >10mg daily dose), cytotoxic chemotherapy, or topical steroid application to the wound surface for >2 weeks duration within 30 days prior to randomization; or anticipated use of the above during the course of the study
- Wound previously treated with CAMPs, tissue engineered, or scaffold materials within 30 days prior to randomization
- Open wound with active infection
- Wound depth with visible exposed bone
- HBOT within 14 days prior to randomization
- Revascularization surgery on the index wound leg within 30 days of screening phase
- Index wound suspicious of neoplasm in the opinion of the principal investigator
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Crossover-oppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Aktiv komparator: No Intervention: Standard of Care
Wound cleansing, Sharps debridement, Dressing for moisture balance, Offloading |
Wound cleansing, Sharps debridement, Dressing for moisture balance, Offloading |
|
Eksperimentell: Intervention: NeoThelium FT & Standard of Care
Wound cleansing, sharps debridement, NeoThelium FT application, Dressing for moisture balance, Offloading |
NeoThelium FT is a dehydrated wound covering derived from donated human placental tissue. NeoThelium FT is a dual-layer membrane with amnion and chorion combination layers. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Complete Wound Closure
Tidsramme: 1-12 weeks
|
The primary endpoint will be the percentage of target ulcers that achieve complete wound closure. |
1-12 weeks
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Percentage Wound Area Change
Tidsramme: 1-12 weeks
|
The percentage change in wound area from TV-1 to TV-13 will be measured weekly using digital photographic planimetry and physical examination. |
1-12 weeks
|
|
Pain Assessment
Tidsramme: Day 0, Day 14, Day 35, Day 56, Day 84
|
Change in pain associated with the target ulcer will be assessed using the Numeric Pain Rating Scale at designated time points |
Day 0, Day 14, Day 35, Day 56, Day 84
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Follow-Up Closure
Tidsramme: 2 weeks
|
Number of wounds remaining closed during the 2-week follow-up |
2 weeks
|
|
Adverse Events and Serious Adverse Events
Tidsramme: Day -14 through 91 days
|
The number and nature of adverse events (AEs) and series adverse events (SAEs) occurring during the study will be tracked and reported. |
Day -14 through 91 days
|
|
Time to Closure
Tidsramme: 1-12 weeks
|
Average number of grafts and/or weeks used to achieve wound closure |
1-12 weeks
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Studieleder: Angelina Ferguson, DNP, SygNola, LLC
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- HEAL
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .